• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will FDA Fast Track for YUTREPIA in Raynaud’s Phenomenon Reshape Liquidia’s (LQDA) Narrative

    Simply Wall St·09/04/2026 11:28:13
    语音播报
    • Liquidia Corporation recently announced that the FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis, and the company plans to start the RE-WARM Phase 2a dose-finding study in October 2026.
    • This designation opens the door to expedited regulatory interactions and potentially faster review timelines for YUTREPIA in a severe condition with limited treatment options and an estimated 30,000 moderate-to-severe patients in the United States.
    • We’ll now examine how Fast Track status for YUTREPIA in systemic sclerosis-related Raynaud's phenomenon may influence Liquidia’s broader investment narrative.

    The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    Liquidia Investment Narrative Recap

    To own Liquidia, you need to believe YUTREPIA can sustain meaningful uptake in PAH and PH-ILD while the company manages payer, pricing and manufacturing risks. The Fast Track designation in systemic sclerosis-related Raynaud's is positive validation of the PRINT platform, but it sits early in development and does not change that near term performance still hinges on continued YUTREPIA execution and the outcome of ongoing patent and reimbursement dynamics.

    Among recent updates, the Q2 2026 results stand out: Liquidia reported US$171.68 million in quarterly revenue and US$74.72 million in net income, underscoring how quickly YUTREPIA has scaled since launch. Against that backdrop, the new Fast Track path in Raynaud's looks more like an incremental, longer term optionality layer than a driver of the current earnings profile or the most immediate share price catalysts tied to legal and payer developments.

    Yet investors should also weigh the possibility that ongoing litigation with United Therapeutics could still result in outcomes that materially affect YUTREPIA’s market access and...

    Read the full narrative on Liquidia (it's free!)

    Liquidia's narrative projects $1.4 billion revenue and $665.8 million earnings by 2029. This requires 68.6% yearly revenue growth and about a $643.5 million earnings increase from $22.3 million today.

    Uncover how Liquidia's forecasts yield a $72.38 fair value, a 5% upside to its current price.

    Exploring Other Perspectives

    LQDA 1-Year Stock Price Chart
    LQDA 1-Year Stock Price Chart

    Before this Fast Track news, the most optimistic analysts were modeling revenue of about US$1.7 billion and earnings near US$917.0 million by 2029, while also flagging that any failure to expand YUTREPIA and L606 into new indications like Raynaud's could cap that upside, so it is worth comparing how your own expectations stack up against such bullish assumptions.

    Explore 5 other fair value estimates on Liquidia - why the stock might be worth just $72.38!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Looking For Alternative Opportunities?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    • Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
    • Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.